Hexamethonium

DB08960ExperimentalSmall molecule

A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been... It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a...

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-2
Curator reviewed
Formula / weight: C₁₂H₃₀N₂ · 202.38 g/mol (avg)

Resolves to

Compound

UNII3C9PSP36Z2CAS60-26-4ChEMBLCHEMBL100622ChEBI5700PubChem3604KEGGC07510

Structure

InChIKeyVZJFGSRCJCXDSG-UHFFFAOYSA-NSMILESC[N+](C)(C)CCCCCC[N+](C)(C)C

Targets

Q15822CHRNA2Q08210Dihydroorotate dehydrogenase (quinone), mitochondrial

What you can answer from here — as of September 12, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,434Drug interactionsStructured to mechanism, not free text

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Hexamethonium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account